Readers share their opinions on some of the most talked-about breast cancer abstracts they’re looking forward to seeing at ESMO 2026.
|Videos|June 1, 2011
Karen Hagemaster on Chemo Documentation Study Results
Author(s)Karen Hagemaster, RN, BSN
Karen Hagemaster From Advocate Good Samaritan Hospital on Chemotherapy Documentation Study Results
Advertisement
Karen Hagemaster, RN, BSN, Oncology Services at Advocate Good Samaritan Hospital discusses the results of the chemotherapy documentation study that focused on a verification process for the safe administration of chemotherapy and compliance with hospital policy and regulatory guidelines.
Advertisement
Related to this article
The FDA granted fast track designation to opamtistomig for first-line treatment of advanced or metastatic biliary tract cancer.
Roswell Park Comprehensive Cancer Center has earned national recognition in 2026 from the American Medical Association as a Joy in Medicine organization.
A planned interim analysis of the radiopharmaceutical RYZ101 showed improved PFS by blinded independent central review vs standard of care.
Conditional approvals in Armenia cover botensilimab plus balstilimab indicated for patients with MSS mCRC without active liver metastases.
The top 5 OncLive TV videos of the week.
Check out this September recap of OncLive’s coverage of the top news and expert insights in gastrointestinal cancers.
The FDA approved atezolizumab plus chemo for stage III colon cancer, cleared a tucatinib-based maintenance regimen for advanced breast cancer, and more.
Advertisement
Advertisement
Trending on OncLive
1
Dr Fradley on Real-World Atrial Fibrillation and Cardiovascular Outcomes in CLL
2
Five Under 5: Top Oncology Videos for the Week of 10/5/2026
3
Armenia Grants First Marketing Authorizations to Botensilimab Plus Balstilimab in Previously Treated MSS mCRC
4
RYZ101 Meets Primary PFS End Point in Phase 3 ACTION-1 Trial for Post–Lutetium-177 GEP-NETs
5